Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039325 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00039325 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 28 participants.
The verdict
NCT00039325, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage IV or recurrent malignant melanoma.
Interventions
- BIOLOGICAL dendritic cell-MART-1 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-03 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039325
The ClinicalTrials.gov registry entry for NCT00039325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dendritic cell-MART-1 peptide vaccine is the first listed.
NCT00039325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039325 about?
NCT00039325 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma". RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating pat...
What is the current status of trial NCT00039325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2002-03. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00039325?
The interventions under investigation include: dendritic cell-MART-1 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00039325?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.